Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Albumin-bound Paclitaxel in Platinum-resistant Recurrent Ovarian Cancer
NCT03942068Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in ovarian cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03942068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942068.